Astaxanthin
Last reviewed
Astaxanthin is a carotenoid antioxidant from microalgae (Haematococcus pluvialis) with the highest lipid-phase antioxidant capacity in the category. It stabilizes mast cells (60-70% inhibition in lab studies) and inhibits collagen-degrading enzymes in human dermal fibroblasts at orally achievable doses, relevant for MCAS and hEDS. ZebraThrive uses 4 mg daily in the PM capsule, with dinner fat for absorption.
At a Glance
Daily Dose
4 mg daily in the PM capsule, taken with dinner fat for absorption (per v7.8 RFQ)
Key Benefits
How It Works
Astaxanthin works as chronic prophylaxis for MCAS by blocking receptor aggregation on mast cell surfaces, interrupting the signaling cascade that leads to histamine release.
For hEDS, it inhibits MMP-1, MMP-3, and MMP-13 while upregulating TIMP-1 (tissue inhibitor of metalloproteinases). In human dermal fibroblasts, this results in a net increase in collagen. It's also an extraordinary antioxidant (6,000x stronger than Vitamin C at quenching singlet oxygen), protecting cardiovascular and cell membrane health.
What the Research Shows
Highly relevant evidence in the exact tissue types affected by hEDS.
Meta-analysis confirms zero blood pressure impact, and perfect safety for orthostatic intolerance.
Meta-analysis of 14 RCTs
No significant effect on systolic or diastolic blood pressure.
Addressing the Triad
Tailored benefits for complex conditions
Astaxanthin stabilizes mast cells through FcεRI-mediated mechanisms: it disrupts the receptor clustering on lipid rafts that triggers degranulation, blocks Lyn and Fyn kinase phosphorylation, and reduces intracellular calcium influx. Lab studies show 60-70% reduction in β-hexosaminidase release (a marker of mast cell degranulation) at achievable concentrations. In mouse models of atopic dermatitis, oral astaxanthin reduced both total mast cell counts and the percentage of degranulated mast cells. The mechanism requires about 4 hours of pre-treatment - it's prophylactic, not acute-rescue. For chronic MCAS management, that's the relevant pattern.
Astaxanthin has strong human dermal fibroblast data - exactly the cell type relevant to hEDS skin findings. In studies on human buttock skin biopsies (Yoon 2014), oral astaxanthin reduced MMP-1 mRNA by 68% and MMP-12 by 77% while increasing procollagen I by 240%. A 2016 study showed similar MMP-1 and MMP-3 reduction in cultured human dermal fibroblasts (Chou 2016). The mechanism - combined matrix protection and pro-collagen support - is exactly the profile an hEDS ingredient should hit. The all-E isomer dominant sourcing matters: 9-cis-rich batches suppress rather than support collagen synthesis.
For POTS, astaxanthin's role is mostly the systemic anti-inflammatory and mast cell layers - many POTS cases overlap with MCAS, and reducing the inflammatory background can quiet the autonomic instability that runs alongside it. Astaxanthin is BP-neutral (a meta-analysis of 14 RCTs found no significant change in systolic or diastolic BP), so there's no orthostatic hypotension concern. Heart rate effects haven't been studied directly. The strongest POTS-relevant case is the dermal microvascular work - astaxanthin supports endothelial function in skin biopsies, a useful background effect for the vascular dysregulation in POTS.
Why We Chose This Form
We use natural astaxanthin from Haematococcus pluvialis algae (not synthetic). The natural form contains the all-E-isomer dominant profile that human studies have validated; synthetic astaxanthin has a different isomer ratio that doesn't reproduce the same clinical results. Our spec requires US-origin sourcing because some European batches have shown rising 9-cis isomer content (up to 29% in 2021 batches) that exceeds the EU safety spec - and the 9-cis isomer suppresses collagen synthesis, which would defeat the point. Take with a fat-containing meal: astaxanthin absorption increases 2-3 times with dietary fat.
Form Comparison
Natural algal (H. pluvialis) with COA-verified isomer profile
All-E-isomer dominant; clinically validated absorption
Synthetic astaxanthin
Different isomer profile; not research-validated for hEDS
Generic softgels with carrageenan or fish oil carriers
Histamine risk from carrageenan or fish-oil fillers
Safety & Interactions
Potential Side Effects
Excellent safety profile at doses up to 24mg daily. Well-tolerated in pediatrics at 4mg.
Drug Interactions
CONTRAINDICATED with Warfarin (case report of INR increase). Minimal CYP450 inhibition at oral doses.
Excipients to Avoid
- Carrageenan softgels
- Soy/Krill oil carriers
Safe Excipients
- HPMC capsules
- MCT or Olive oil lipid carrier
Pre-treatment is required for mast cell effects (prophylaxis, not rescue).
How to Start
| Protocol Step | Suggested Dosage | Key Notes |
|---|---|---|
| Ongoing | 4 mg daily in the PM capsule, taken with dinner fat for absorption (per v7.8 RFQ) | Standard PM dose with dinner |
"Inflammatory marker changes within weeks; skin/collagen benefits typically require 8-12 weeks."
State of the Evidence
Zero direct studies in hEDS/POTS/MCAS patients. Concerns exist regarding 'Z-isomers' which may suppress collagen synthesis (always select all-E products). TGF-β pathway concerns in liver models are not currently reflected in skin fibroblast data.
- [1]Mast cell stabilization IC50 studyPMID: 19700409
Sakai et al. (2009)
- [2]Human dermal fibroblast MMP inhibitionPMID: 27322248
Chou et al. (2016)
- [3]No effect of astaxanthin on blood pressure (Meta-analysis)PMID: 32755613
Xia et al. (2020)
- [4]Safety review of astaxanthin (87 studies)PMID: 31788888
Brendler et al. (2019)
- [5]Z-isomer collagen suppression concernPMID: 37305308
Honda et al. (2023)
- [6]Yoshihisa et al., 2016PMID: 27023003
- [7]Yoon et al., 2014PMID: 24955642
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .